Want to see GB:BVXP full AI Analyst Report?
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,300.00 p - 2,800.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£80.99M
Enterprise Value95.58 p
Total Cash (Recent Filing)£5.30M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)10.9
Beta0.62
Next Earnings
Oct 26, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield9.68%
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsExceptionally high gross and net margins indicate durable pricing power and operational discipline. Such elite profitability supports strong internal cash generation, funds dividends or reinvestment, and provides a long-term cushion against cyclical revenue dips, sustaining returns to shareholders.
Conservative Balance Sheet (no Debt)A zero-debt balance sheet delivers financial resilience and strategic optionality. Low leverage reduces bankruptcy risk, preserves capacity to fund development or pay dividends from cash, and allows measured capital allocation decisions that support long-term stability and investor returns.
Strong Cash ConversionHigh and reliable cash conversion confirms earnings quality and enables sustainable shareholder distributions and R&D funding. Predictable cash generation from royalties and reagent sales creates durable free cash flow that supports capital allocation over multi-year horizons.
Bears Say
Recent Revenue & FCF SlowdownA measurable decline in revenue and free cash flow in 2025 signals weakening operating momentum. If persistent, slower top-line and cash trends can erode margin leverage, reduce reinvestment capacity, and pressure dividends or partnership negotiations over a multi-quarter to multi-year timeframe.
Shrinking Equity And AssetsA contracting equity and asset base can constrain balance-sheet flexibility for scaling production, funding new antibody discovery, or pursuing collaborations. Over time, a smaller asset base may limit growth capacity and increase sensitivity to revenue volatility or funding needs.
Customer/royalty Concentration RiskRevenue dependency on external diagnostic manufacturers and the adoption of a limited set of assays creates structural concentration risk. Long assay lifecycles cut both ways: durable annuities when successful, but elevated downside if key customers lose share or assays are replaced, pressuring recurring income.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 2800.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £80.99M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 96 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.516 p by 0.168 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 70 p which represents an annual dividend yield of 9.68%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 0.66.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.516 p. Following the earnings report the stock price went up 6.909%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth £9.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
9.68%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―